Back to Search
Start Over
Pericarditis during chemoimmunotherapy for non-small cell lung cancer: an adverse event to prevent and recognise.
- Source :
-
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 May; Vol. 149, pp. 114-116. Date of Electronic Publication: 2021 Apr 12. - Publication Year :
- 2021
-
Abstract
- Competing Interests: Conflict of interest statement The authors F.J., S.C., P.D.S. and A.L. declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The author S.N. is on the speakers' bureau and reports an advisory role for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Roche, Takeda, AbbVie, Pfizer, MSD, Bayer and BMS.
- Subjects :
- Carcinoma, Non-Small-Cell Lung immunology
Carcinoma, Non-Small-Cell Lung secondary
Cardiotoxicity
Glucocorticoids administration & dosage
Humans
Lung Neoplasms immunology
Lung Neoplasms pathology
Male
Middle Aged
Pericarditis diagnosis
Pericarditis drug therapy
Risk Factors
Treatment Outcome
Antibodies, Monoclonal, Humanized adverse effects
Antineoplastic Combined Chemotherapy Protocols adverse effects
Carcinoma, Non-Small-Cell Lung drug therapy
Immune Checkpoint Inhibitors adverse effects
Lung Neoplasms drug therapy
Pericarditis chemically induced
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0852
- Volume :
- 149
- Database :
- MEDLINE
- Journal :
- European journal of cancer (Oxford, England : 1990)
- Publication Type :
- Report
- Accession number :
- 33857885
- Full Text :
- https://doi.org/10.1016/j.ejca.2021.03.004